Printer Friendly

Endologix' Ovation LUCY Study Shows Positive Results in Evaluation of Endovascular Aneurysm Repair in Women.

M2 PHARMA-June 2, 2017-Endologix' Ovation LUCY Study Shows Positive Results in Evaluation of Endovascular Aneurysm Repair in Women


- US-based aortic disorders treatments developer Endologix, Inc. (NASDAQ: ELGX) has announced 30-day results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for Abdominal Aortic AneurYsm Repair) study showed that at least 28% more women became eligible for minimally-invasive endovascular aneurysm repair (EVAR) when using the Ovation Abdominal Stent Graft System, the company said.

The Ovation System is designed to better suit female anatomy than traditional EVAR options and demonstrated lower mortality and complications when compared to previous EVAR studies.

The LUCY study is the first to specifically evaluate EVAR outcomes in women, who have historically been underrepresented in EVAR clinical trials.

Female anatomy may be more challenging for most commercial EVAR treatments, leading to less eligibility for EVAR and greater mortality, major complications, and readmissions, when compared to men.

The LUCY study is a prospective, consecutively enrolling, non-randomized, multi-center, post-market registry evaluating the Ovation Platform for the endovascular treatment of abdominal aortic aneurysms (AAA) in women. Longer-term data from the LUCY study will be shared after the one-year follow-up.

Endologix develops and manufactures minimally invasive treatments for aortic disorders. The company's focus is endovascular stent grafts for the treatment of AAA, a weakening of the wall of the aorta resulting in a balloon-like enlargement.

If left untreated, it becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 2, 2017
Previous Article:Ralexar Therapeutics Begins Patient Enrollment for Phase 2b Study of Topical Gel for Treatment of Atopic Dermatitis.
Next Article:Deciphera Closes USD 52m Series C Financing to Advance Oncology Pipeline.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters